News | August 14, 2014

Study Shows CRT-D Devices With Medtronic AdaptivCRT Associated With Reduced AF Costs

Study supplements earlier data showing reduction in hospital readmissions for heart failure patients with AdaptivCRT technology

August 14, 2014 — New data from the Medtronic Inc. Adaptive CRT trial show a 61 percent (p=0.01) lower risk of atrial fibrillation (AF)-related problems in patients who receive a cardiac resynchronization therapy-defibrillator (CRT-D) with the Medtronic-exclusive AdaptivCRT algorithm compared to conventional biventricular pacing therapy. Presented at Cardiostim/EHRA Europace 2014, World Congress in electrophysiology and cardiac techniques, the data also indicate a 55 percent relative reduction in healthcare utilizations (HCUs), including hospitalizations, emergency department or clinic visits, when patients have devices with AdaptivCRT.

Patients with heart failure, which is a progressive disease, are more likely than the general population to develop AF. AF is associated with worsening heart failure symptoms and higher mortality, along with patients' increased use of healthcare resources. Previous data from this trial showed patients with heart failure who received the AdaptivCRT technology were at a 46 percent lower risk of spending 48 consecutive hours or more in AF compared to conventional CRT patients [1].

According to the analysis of 476 patients, potential use of healthcare resources because of AF are reduced with the AdaptivCRT technology; specific data was presented for the healthcare systems in the United States and Germany, which showed AF-related provider cost savings of $630 per patient and €130 over 24 months, respectively. Nearly all of these cost savings (92 percent in the United States, 93 percent in Germany) were from a reduction in hospitalizations. 

"The study results are clear in showing that CRT devices with adaptive algorithms reduce the risk of atrial fibrillation adverse events and related costs," said Prof. Dr. Med. Bernd Lemke, head of the Department of Cardiology at Lüdenscheid Hospital, Germany. "On an individual level, the algorithm's personalized therapy helps keep more patients out of the hospital. On a system-level, this results in savings and less use of healthcare resources."

Recent data presented at Heart Rhythm 2014 from the Adaptive CRT trial also showed that the AdaptivCRT feature reduced 30-day readmissions for heart failure by nearly half [2], and 30-day readmissions for all-cause hospitalizations by more than 40 percent [2], which are both noteworthy since readmissions within 30 days of discharge may result in reduced or no payment under many payment settings. Heart failure leads to more than 1 million hospitalizations in the United States yearly [3], and U.S. patients are readmitted on average 1.23 times the first year after initial heart failure diagnosis [4]. As a consequence, heart failure is currently the fourth-leading cause of 30-day hospital readmissions [5] and the leading cause of readmission of Medicare patients [6]. More than 60 percent of patients indicated for any type of CRT therapy do not receive it [7].

Because of the favorable evidence showing reduction in AF incidence and all-cause hospitalizations among patients with the AdaptivCRT technology, Medtronic plans to conduct a global study of 3,000 patients to evaluate the superiority of CRT with AdaptivCRT therapy in reducing heart failure events and mortality, compared to conventional bi-ventricular pacing.

The AdaptivCRT feature, found on market-released Medtronic Viva CRT-D and Viva CRT-P devices, works by preserving normal heart rhythms and automatically adjusting to the patient's needs every minute, creating a customized therapy for each patient [8]. The research presented today builds on previous findings from the Adaptive CRT trial that showed the benefits of the AdaptivCRT algorithm, including:

  • AdaptivCRT increases CRT response rate by 12 percent [9];
  • Patients with AdaptivCRT have demonstrated a 21 percent reduction in heart failure hospitalization [10] and a reduced risk of death [9];
  • Patients with the AdaptivCRT technology have a 46 percent reduced risk of AF1.

"As today's healthcare environment evolves and more focus is placed on curbing readmission rates, hospital administrators and payers must increasingly focus on both the health benefits and quality of life of individual patients and the long-term cost savings of effective treatments," said Sheri Dodd, vice president of Clinical Research, Healthcare Economics and Policy for the Cardiac Rhythm Disease Management business at Medtronic. "Hospital administrators must increasingly look to new solutions for tackling heart failure and associated costs, and this is made easier with this data showing the benefit of implanting devices that have the adaptive algorithm."

For more information:


1.Martin D, et al. Can Adaptive Cardiac Resynchronization Therapy Reduce Atrial Fibrillation Risk? Circulation. 2013;128(22S):A17740.

2.Starling RC, et al. Impact of Novel Adaptive Optimization Algorithms on 30-day Readmissions:  Evidence from the Adaptive CRT Trial. Heart Rhythm 2014;11(5)(suppl):S155.

3.Hall MJ., Levant S., DeFrances CJ. Hospitalization for congestive heart failure: United States, 2000-2010. NCHS data brief, no 108. Hyattsville, MD: National Center for Health Statistics, 2012.

4.Hunt P, et al. Circ Cardiovasc Qual Outcomes. 2013;6:A172.

5.Elixhauser A., Steiner C. Readmissions to U.S. Hospitals by Diagnosis, 2010. Healthcare Cost and Utilization Project, Statistical Brief #153. Agency for Healthcare Research and Quality. 2013.

6.Desai A., Stevenson L. Rehospitalization for Heart Failure. Circulation 2012 Jul 24;126(4):501-6;

7.Fonarow GC, et al. Heart Failure Care in the Outpatient Cardiology Practice Setting: Findings From IMPROVE HF. Circ Heart Fail. 2008;1:98-106.

8.Abraham WT, Fisher WG, Smith AL, et al. Cardiac resynchronization in chronic heart failure. N Engl J Med. June 13, 2002;346(24): 1845-1853.

9.Birnie D, Lemke B, Aonuma K, et al. Clinical outcomes with synchronized left ventricular pacing: Analysis of the adaptive CRT trial. Heart Rhythm. September 2013;10(9):1368-1374.

10.Tarab AD, Dougher CE, Rogers TB, et al. Budget impact of selecting cardiac resynchronization therapy (CRT) devices with adaptive ("aCRT") programming algorithms under the United States Medicare Payment Setting. Value in Health. November 2012;15(7):A349.

Related Content

Biotronik Announces U.S. Launch of Edora HF-T QP CRT Pacemaker
Technology | Cardiac Resynchronization Therapy Devices (CRT)| August 21, 2017
Biotronik announced U.S. Food and Drug Administration (FDA) approval and commercial availability of Edora HF-T QP, an...
Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
The FDA is concerned about cybersecurity of ICDs and cyber security of other medical devices.
Feature | Cybersecurity| August 16, 2017 | Dave Fornell
There is growing concern among patients and regulators that medical devices, especially implantable electrophysiology
Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study| August 16, 2017
Aug. 16, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking Clinic
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Abbott Initiates First Clinical Trial of Clip-Based Tricuspid Repair System
News | Heart Valve Technology| August 09, 2017
Abbott announced that the first patient has been enrolled in a clinical study to evaluate a minimally invasive clip-...
Overlay Init